Overview

There has been a major shift in the emphasis of U.S. FDA CGMP compliance audits over the past few years. 

This change in focus has a major impact on individual compliance objectives, efforts and measurements of success. The Agency has come under increasing negative publicity due to recent food, device, drug, vacine and infant formula shortage problems. This  affects the Agency's approach to audits and their expectations for companies, with emphasis on the key CGMP areas under QSIT.

This course focuses on identifying FDA inspection criteria, resources (including key standard operating procedures such as CP 7382.845) and practices used to plan, conduct, and assess inspections of medical device manufacturers. It  walks participants through a "typical" new, tougher CGMP compliance audit. It will figuratively "look over the shoulder" of an investigator as they walk though a device plant and perform an audit, based on the always changing regulatory climate.

Why you should attend

Recent US FDA inspections indicate the past ways of doing things will no longer be acceptable. Increasingly reports from the field indicate that the Agency is using high-profile cases to drive compliance to smaller companies and suppliers. See how the on-site CGMP compliance audit is changing and the FDA focus is shifting. Recognizing what to expect during an FDA inspection enables a medical device manufacturer to effectively prepare for the inspection.

This Seminar will focus on how to prepare domestic and foreign medical device manufacturers selling to the U.S. to recognize and prepare for FDA pre- and post-market inspections.

Who Will Benefit

• Senior Management
• Regulatory Affairs
• Quality Assurance
• Production
• Engineering
• All Personnel Involved in a U.S. FDA-Regulated Environment

Speaker Profile